Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
bifidobacterium, lactobacillus, enterococcus and bacillus cereus tablets, live
- Development stage
- Unknown
- Lead developer
- Hangzhou Grand Biologic Pharmaceutical
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Bifidobacterium, Lactobacillus, Enterococcus and Bacillus cereus tablets (live) is a quadruple probiotic pharmaceutical product primarily developed and manufactured in China. It is composed of four live bacterial strains: *Bifidobacterium infantis*, *Lactobacillus acidophilus*, *Enterococcus faecalis*, and *Bacillus cereus*. The product is designed to treat intestinal flora imbalance (dysbiosis) and associated symptoms such as acute or chronic diarrhea, constipation, and abdominal distension. Its mechanism of action involves the direct replenishment of beneficial commensal bacteria and the consumption of oxygen by *Bacillus cereus*, which facilitates the growth of anaerobic species like *Bifidobacterium*. It is frequently used as a control or adjunctive therapy in clinical trials for irritable bowel syndrome (IBS) and other gastrointestinal conditions in China.
- Brand names
- Siliankang
- Other names
- Bifidobacterium Bacillus quadruplex live bacterial tabletsSi Lian KangBifidobacterium tetravaccine
Beyond the preview
Go deeper on bifidobacterium, lactobacillus, enterococcus and bacillus cereus tablets, live.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on bifidobacterium, lactobacillus, enterococcus and bacillus cereus tablets, live.